Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition
Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company ...
Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company ...
Repare Therapeutics has three cancer drug candidates in the clinic and another one expected to enter Phase 1 by the ...
Copyright © 2024 EuroAsia24 News.
EuroAsia24 News is not responsible for the content of external sites.